Eli Lilly (LLY) reported combined sales of its GLP-1 drugs, Mounjaro and Zepbound, reaching $36.5 billion in 2025, representing around 56% of its total revenue. The company anticipates continued growth from these drugs and newly approved therapies, projecting overall revenues of $80-$83 billion and EPS of $33.50-$35.00 for 2026.
AbbVie (ABBV) achieved combined sales from its immunology drugs Skyrizi and Rinvoq totaling $26 billion in 2025, expected to exceed $31 billion in 2026. Following the loss of exclusivity for Humira, AbbVie has successfully pivoted and expects overall revenue growth of approximately 9.5% in 2026.
Comparatively, LLY’s stock has increased 9.2% over the past year, while ABBV’s stock has risen 2.0%. AbbVie offers a higher dividend yield of 2.3% compared to Lilly’s 0.8%, although LLY trades at a higher valuation with a forward P/E ratio of 25.12 versus ABBV’s 13.75.
